New oxidation methods streamline synthesis of important compoundsAugust 03, 2007CHAMPAIGN, Ill. - One of the fundamental challenges facing organic synthesis in the 21st century is the need to significantly increase the efficiency with which carbon frameworks can be constructed and functionalized. Chemists at the University of Illinois are helping to meet this challenge by developing a class of carbon-hydrogen catalysts that are highly selective, reactive and tolerant of other functionality. The catalysts also offer a new strategy for streamlining the synthesis of important compounds, including drugs and pharmaceuticals, by avoiding the functional group manipulations required for working with oxidized materials. "We are creating a toolbox of catalytic reactions that allow us to go directly from a carbon-hydrogen bond to a carbon-oxygen bond or to a carbon-nitrogen bond," said M. Christina White, a professor of chemistry at Illinois. "By offering fewer steps, fewer functional group manipulations and higher yields, this toolbox will change the way chemists make molecules."
Currently, chemists must make molecules by beginning with something that is already oxidized. But, having to start with that functionality means it must be carried - and protected - throughout the entire synthetic sequence. And that costs reagents, time, money and manpower, in addition to being inherently inefficient. "Unlike standard synthetic methods, we don't have to carry the functionality throughout the entire sequence," White said. "Instead, we carry latent functionality as a carbon-hydrogen bond. Then, at a late stage in the synthesis, we remove the hydrogen and replace it with oxygen or nitrogen - right where we need it for the next chemical reaction." In the June 13 issue of the Journal of the American Chemical Society, White and graduate student Kenneth J. Fraunhoffer describe the catalytic pathway they used to synthesize a derivative of the chemotherapeutic reagent acosamine. They were able to eliminate all of the functional group manipulations and cut by one-half the number of steps required, while maintaining the same purity and yield. White has also used her catalyst to streamline the synthesis of a peptidase inhibitor drug candidate, a nucleotide-sugar L-galactose, and is currently working on the antibiotic erythromycin A. White's research is funded by the Henry Dreyfus Foundation, the A.P. Sloan Foundation, the University of Illinois, Merck Research Laboratories, the National Institutes of Health and the National Science Foundation. Editor's note: To reach M. Christina White, call 217-333-6173; e-mail: white@scs.uiuc.edu To view or subscribe to the RSS feed for Science News at Illinois, please go to: http://webtools.uiuc.edu/rssManager/608/rss.xml University of Illinois at Urbana-Champaign | |||||||||||||||||||||
|
Related Synthesis News Articles Scientists peel away the mystery behind gold's catalytic prowess Few materials have exercised as much of a hold on the human imagination, or on human history, as has gold. Atomic structure of the mammalian 'fatty acid factory' determined Mammalian fatty acid synthase is one of the most complex molecular synthetic machines in human cells. It is also a promising target for the development of anti-cancer and anti-obesity drugs and the treatment of metabolic disorders. Nature inspires new highly specific drugs and organic products The best place to seek novel compounds for pharmaceutical drugs, alternative energy sources, and a host of industrial applications, is within natural systems that have evolved over millions of years. The first autism disease genes The autistic disorder was first described, more than sixty years ago, by Dr. Leo Kanner of the Johns Hopkins Hospital (USA), who created the new label 'early infantile autism'. Molecular sleuths track evolution through the ribosome A new study of the ribosome, the cell's protein-building machinery, sheds light on the oldest branches of the evolutionary tree of life and suggests that differences in ribosomal structure between the three main branches of that tree are "molecular fossils" of the early evolution of protein synthesis. Caltech engineers build mini drug-producing biofactories in yeast Researchers at the California Institute of Technology have developed a novel way to churn out large quantities of drugs, including antiplaque toothpaste additives, antibiotics, nicotine, and even morphine, using mini biofactories--in yeast. Chemists move closer toward developing safer, fully-synthetic form of heparin Chemists are reporting a major advance toward developing a safer, fully-synthetic version of heparin, the widely used blood thinner now produced from pig intestines. The U. S. Food and Drug Administration last spring linked contaminated batches of the animal-based product, imported from China, to more than 80 deaths and hundreds of allergic reactions among patients exposed to the drug for kidney dialysis and other conditions. Researchers create safer alternative to heparin Robert Linhardt has spent years stitching together minuscule carbohydrates to build a more pure and safer alternative to the commonly used and controversial blood thinner heparin. Turning Waste Material into Ethanol Say the word "biofuels" and most people think of grain ethanol and biodiesel. But there's another, older technology called gasification that's getting a new look from researchers at the U.S. Department of Energy's Ames Laboratory and Iowa State University. By combining gasification with high-tech nanoscale porous catalysts, they hope to create ethanol from a wide range of biomass, including distiller's grain left over from ethanol production, corn stover from the field, grass, wood pulp, animal waste, and garbage. Study reveals surprising details of the evolution of protein translation A new study of transfer RNA, a molecule that delivers amino acids to the protein-building machinery of the cell, challenges long-held ideas about the evolutionary history of protein synthesis. More Synthesis News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||